Gender aspects of CGRP in migraine

被引:92
|
作者
Labastida-Ramirez, Alejandro [1 ]
Rubio-Beltran, Eloisa [1 ]
Villalon, Carlos M. [2 ]
MaassenVanDenBrink, Antoinette [1 ]
机构
[1] Erasmus MC, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands
[2] Cinvestav IPN, Dept Farmacobiol, Unidad Sur, Mexico City, DF, Mexico
关键词
CGRP; estrogen; migraine; ovarian steroid hormones; trigeminovascular system; GENE-RELATED PEPTIDE; DORSAL-ROOT GANGLIA; RANDOMIZED CONTROLLED-TRIAL; FEMALE SEX-HORMONES; RECEPTOR ANTAGONIST TELCAGEPANT; SPINAL TRIGEMINAL NUCLEUS; DERMAL BLOOD-FLOW; CALCITONIN-GENE; MONOCLONAL-ANTIBODY; MESSENGER-RNA;
D O I
10.1177/0333102417739584
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood. In this respect, calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology and, more recently, the functional interactions between ovarian steroid hormones, CGRP and the trigeminovascular system have been recognized and studied in more detail. Aims To provide an overview of CGRP studies that have addressed gender differences utilizing animal and human migraine preclinical research models to highlight how the female trigeminovascular system responds differently in the presence of varying ovarian steroid hormones. Conclusions Gender differences are evident in migraine. Several studies indicate that fluctuations of ovarian steroid hormone (mainly estrogen) levels modulate CGRP in the trigeminovascular system during different reproductive milestones. Such interactions need to be considered when conducting future animal and human experiments, since these differences may contribute to the development of gender-specific therapies.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 50 条
  • [41] CGRP antagonists and antibodies for the treatment of migraine
    Vecsei, Laszlo
    Szok, Delia
    Csati, Anett
    Tajti, Janos
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (01) : 31 - 41
  • [42] CGRP Mechanism Antagonists and Migraine Management
    Nazia Karsan
    Peter J. Goadsby
    Current Neurology and Neuroscience Reports, 2015, 15
  • [43] Antibodies against CGRP for prevention of migraine
    Chaplin, Steve
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2019, 23 (02) : 27 - 31
  • [44] CGRP antagonists in the acute treatment of migraine
    Lipton, RB
    Dodick, DW
    LANCET NEUROLOGY, 2004, 3 (06): : 332 - 332
  • [45] CGRP antibodies in migraine prophylaxis The new standard in migraine treatment?
    Hamann, Till
    Rimmele, Florian
    Juergens, Tim Patrick
    SCHMERZ, 2022, 36 (01): : 59 - 72
  • [46] CGRP Mechanism Antagonists and Migraine Management
    Karsan, Nazia
    Goadsby, Peter J.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2015, 15 (05) : 1 - 9
  • [47] CGRP receptors and TRP channels in migraine
    Geppetti, Pierangelo
    Benemei, Silvia
    De Cesaris, Francesco
    JOURNAL OF HEADACHE AND PAIN, 2015, 16 : 1
  • [48] Effect of rizatriptan on CGRP level in migraine
    Stepien, A
    Jagustyn, P
    Trafny, A
    Widerkiewicz, K
    CEPHALALGIA, 2003, 23 (07) : 738 - 738
  • [49] Correlation between CGRP and migraine attacks
    Edvinsson, L
    CEPHALALGIA, 2005, 25 (03) : 163 - 164
  • [50] CGRP and migraine: from bench to bedside
    Edvinsson, L.
    REVUE NEUROLOGIQUE, 2021, 177 (07) : 785 - 790